News
ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor
Data published in the Journal of ImmunoTherapy of Cancer confirms…
Novo Holdings continues to back Biomason by participating in its US$65M Series C Financing
Funds will accelerate wide-scale adoption and commercialisation…
Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency
February 24, 2022
Stockholm, Sweden, February 24, 2022 –…
Versameb appoints world leading experts in urology to Advisory Board
Appointment of experts to support development of lead candidate…
Theragnostics Announces US FDA Approval for its Radiodiagnostic Imaging Drug NephroScanTM (Kit for the Preparation of Technetium Tc 99m Succimer Injection)
NephroScan is now US FDA approved for the preparation of Tc-99m…
Study indicates that AMSilk engineered silk implant coatings can prevent infection
Repellence properties of silk coatings reduced microbial…
TargED raises €39 million in a series A investment round
TargED is extremely pleased and proud to have raised €39 million…
ISA Pharmaceuticals to Attend Multiple In Person Conferences in Early 2022
Oegstgeest, the Netherlands, February 17, 2022 – ISA Pharmaceuticals…
Versameb to present at the Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting
Data demonstrates first-in-class potential as a regenerative…
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Curve’s innovative mammalian cell drug discovery platform…
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
Financing co-led by UCB Ventures and Ysios Capital…
Theragnostics Announces that its Radiotherapeutic for Treatment of Glioblastoma Multiforme has been Awarded UK’s MHRA Innovation Passport
Promising non-clinical results support Phase 1 clinical study…
Destiny Pharma: Positive feedback from European Medicines Agency on XF-73 Nasal gel Phase 3 programme
Positive feedback from European Medicines Agency on XF-73 Nasal…
vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Improved neurologic outcome in young adults (18-39 years)…
Novo Nordisk Fonden – Record year for industrial biotechnology grants and investments
Biotechnology – and in particular industrial biotechnology…
Synaffix Inks Deal with MacroGenics to Enable Next Generation ADCs
Synaffix to provide access to proprietary antibody-drug conjugate…
eTheRNA Announces Research Agreement with Merck to access mRNA technologies
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce…
Destiny Pharma announces positive results in XF-73 Dermal safety study from ongoing agreement with US Government’s NIAID
Brighton, United Kingdom, 1 February 2022 - Destiny Pharma plc…
CellCentric secures investment from the American Cancer Society’s impact venture capital fund
Inobrodib is the first drug to target p300/CBP, a new way to…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
